JFNAX
Janus Henderson Global Life Sciences Fund
JANUS INVESTMENT FUND
Expense ratio1
1.00%
Net assets2
$5.20B
Holdings2
103
Category
US Equity
2025 return3
24.61%

Investment objective & strategy

As of Jan. 28, 2026 · prospectus

Objective. Janus Henderson Global Life Sciences Fund seeks long-term growth of capital.

Strategy. The Fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that portfolio management believes have a life science orientation. In the Funds pursuit of companies with a life science orientation, the Fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the life sciences sector, which may include companies in the following industry groups: pharmaceuticals; biotechnology; health care services; agriculture; cosmetics/personal care; and medical devices. Generally speaking, the life sciences relate to maintaining or improving quality of life. So, for example, companies with a life science orientation include companies … The Fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that portfolio management believes have a life science orientation. In the Funds pursuit of companies with a life science orientation, the Fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the life sciences sector, which may include companies in the following industry groups: pharmaceuticals; biotechnology; health care services; agriculture; cosmetics/personal care; and medical devices. Generally speaking, the life sciences relate to maintaining or improving quality of life. So, for example, companies with a life science orientation include companies engaged in research, development, production, or distribution of products or services related to health and personal care, medicine, or pharmaceuticals. The Fund implements its investment policies by investing primarily in equity securities of U.S. and foreign companies selected for their growth potential. The Fund normally invests in issuers from several different countries, which may include the United States. An issuer is deemed to be economically tied to a country or countries if one or more of the following tests are met: (i) the issuer is organized in, or its primary business office or principal trading market of its equity is located in, the country; (ii) a majority of the issuers revenues are derived from one or more countries; or (iii) a majority of the issuers assets are located in one or more countries. The Fund may invest in shares of companies through initial public offerings, private placements, and secondary offerings. Portfolio management applies a bottom-up approach in choosing investments. In other words, portfolio management looks at companies one at a time to determine if a company is an attractive investment opportunity and if it is consistent with the Funds investment policies. In conducting the bottom-up analysis, portfolio management considers factors including a companys growth potential, the strength of a companys management, and a companys sustainable competitive advantages, returns on investment capital, and cash flow generation. As part of its investment process, portfolio management considers environmental, social, and governance (ESG) risks and opportunities (ESG Factors) that it believes are financially material, alongside other fundamental investment factors. Examples of potential financially material ESG Factors include: corporate governance, company culture, exposure to climate change, and human capital management. To assess ESG Factors, portfolio management uses issuer reports, third-party data, and internally-generated analyses and may engage directly with issuers. ESG Factors are one of many considerations in the investment decision-making process, may not be determinative in deciding to include or exclude an investment from the portfolio, and may not be considered for every investment decision. Portfolio management also applies screens, which incorporate third-party inputs, to (i) seek to avoid investing in issuers that are United Nations Global Compact violators and (ii) seek to invest at least 80% of the Funds net assets, under normal circumstances, in issuers with an MSCI (or an equivalent third-party data provider, as determined by portfolio management) ESG rating of BB or higher. The Fund will generally consider selling a stock when, in portfolio managements opinion, the stock shows declining fundamentals, its competitive advantages have deteriorated, or if the stock reaches its targeted value. The Fund will also consider selling a stock if, in portfolio managements opinion, a superior investment opportunity arises. The Fund may seek to earn additional income through lending its securities to certain qualified broker-dealers and institutions, in an amount equal to up to one-third of its total assets as determined at the time of the loan origination.

Top holdings

As of March 31, 2026 · N-PORT
SecurityTickerValue% of fund
LILLY ELI and CO $459.41M 8.84%
JOHNSON&JOHNSON $378.94M 7.29%
AstraZeneca PLC ORD USD0.25 AZN LN $238.63M 4.59%
ABBVIE INC $210.53M 4.05%
UNITEDHEALTH GRP $162.69M 3.13%
Novartis AG $148.41M 2.86%
THERMO FISHER SCIENTIFIC INC $130.39M 2.51%
PRAXIS PRECISION MEDICINES INC $127.26M 2.45%
ARGENX SE SPONSORED ADR $124.75M 2.40%
ABBOTT LABS $124.49M 2.40%
View all holdings →

Allocation by sector

As of March 31, 2026 · N-PORT
View portfolio breakdown →

Portfolio moves

Dec 31, 2025 → Mar 31, 2026
Opened
9
Exited
13
Increased
43
Decreased
35
Unchanged
17

How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.

View portfolio moves →

Similar funds

Funds whose portfolios most overlap this one, by weight

Footnotes

  1. Expense ratio as of January 28, 2026, from the fund's prospectus.
  2. Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
  3. Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).

Machine-readable: JSON · Markdown. Programmatic access via the agent surface.